Business
Mesoblast now expects to release Ryoncil ruling on Monday – Stockhead
Mesoblast is in a trading halt, but doesn’t expect to announce the FDA’s decision on Ryoncil until Monday Approval of the stem cell treatment to treat pediatric…
Link copied toclipboard
- Mesoblast is in a trading halt, but doesn’t expect to announce the FDA’s decision on Ryoncil until Monday
- Approval of the stem cell treatment to treat pediatric graft-versus-host disease would be transformative for the company
- A reason for the delay wasn’t given
Mesoblast (ASX:MSB) shareholders have a few more sleepless nights ahead of them.
The closely watched biotech went into a trading halt this morning in relation to the US Food and …
Continue Reading
-
Noosa News21 hours agoHow Lily Steele-Park took her rapist to court and won
-
Noosa News24 hours agoStar’s Brisbane casino has been in the headlines for months: What’s the latest?
-
Noosa News21 hours agoE-biker charged with riding dangerously, assaulting cop
-
Business23 hours ago5 things to watch on the ASX 200 on Tuesday 8 July 2025